Skip to content
AnalystLens

Moderna, Inc. 8-K Report, Financial Results (Jan 10, 2022)

Reports
Earnings & Results·Regulation FD·Exhibits & Filings
Filing Date
Filed January 10, 2022
Period End
January 10, 2022
Security
MRNA
In the record · 2018–202610-K910-Q238-K117

MRNA filed 9 annual reports (10-K), 23 quarterly reports (10-Q) and 117 current reports (8-K) between 2018 and 2026.

  1. Material agreement8-K · Aug ’20Aug ’20
  2. Leadership change8-K · Sep ’22Sep ’22
  3. Leadership change8-K · Sep ’26Sep ’26

01—Abstract

Summary

Summary of the 8-K filed January 10, 2022. Cited figures are marked; the original filing is the authoritative source.

Moderna, Inc. (MRNA) filed an 8-K on January 10, 2022, providing preliminary financial results and operational updates for the fiscal year ended December 31, 2021.

The company announced the worldwide delivery of approximately 807 million doses of its COVID-19 vaccine, equivalent to roughly 790 million doses on a 100 µg basis. This significant delivery volume translates into robust preliminary product sales of approximately $17.5 billiona for the fiscal year 2021, driven by its COVID-19 vaccine. These figures are unaudited and preliminary, with the full financial audit still in progress.

While these numbers provide an early look at Moderna's strong performance in 2021, investors should be aware that the final audited results may differ. The announcement was made in conjunction with the Company's presentation at the 40th Annual J.P. Morgan Healthcare Conference.

02—Key points

Key Highlights

  1. Moderna delivered approximately 807 million doses of its COVID-19 vaccine globally in fiscal year 2021.
  2. Preliminary product sales for fiscal year 2021 are estimated at approximately $17.5 billion.
  3. The strong sales are primarily attributed to the company's COVID-19 vaccine.
  4. The provided financial information is unaudited and preliminary.
  5. Final audited financial statements for fiscal year 2021 are still pending.
  6. The update was communicated via a press release during the 40th Annual J.P. Morgan Healthcare Conference.

03—Questions

Frequently Asked Questions

  1. What were Moderna's preliminary sales for 2021?

    Moderna reported preliminary product sales of approximately $17.5 billion for the fiscal year ended December 31, 2021, primarily from its COVID-19 vaccine.

  2. How many COVID-19 vaccine doses did Moderna deliver in 2021?

    The company delivered approximately 807 million doses of its COVID-19 vaccine worldwide during the fiscal year 2021.

  3. Is the financial information provided in the 8-K final?

    No, the financial information presented is unaudited and preliminary. The company's audit for the fiscal year 2021 is ongoing, and the final audited results may differ.

  4. Where was this information announced?

    This information was announced in a press release issued on January 10, 2022, in connection with Moderna's presentation at the 40th Annual J.P. Morgan Healthcare Conference.

04—Continue

← View all 8-K filings